218 related articles for article (PubMed ID: 15757449)
1. Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 4: p53 signaling pathway.
Newton HB
Expert Rev Anticancer Ther; 2005 Feb; 5(1):177-91. PubMed ID: 15757449
[TBL] [Abstract][Full Text] [Related]
2. Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 5: apoptosis and cell cycle.
Newton HB
Expert Rev Anticancer Ther; 2005 Apr; 5(2):355-78. PubMed ID: 15877531
[TBL] [Abstract][Full Text] [Related]
3. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors.
Newton HB
Curr Opin Investig Drugs; 2007 Dec; 8(12):1009-21. PubMed ID: 18058572
[TBL] [Abstract][Full Text] [Related]
4. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: Growth factor and Ras signaling pathways.
Newton HB
Expert Rev Anticancer Ther; 2003 Oct; 3(5):595-614. PubMed ID: 14599084
[TBL] [Abstract][Full Text] [Related]
5. Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 3: brain tumor invasiveness.
Newton HB
Expert Rev Anticancer Ther; 2004 Oct; 4(5):803-21. PubMed ID: 15485315
[TBL] [Abstract][Full Text] [Related]
6. Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy.
Wiman KG
Adv Cancer Res; 2007; 97():321-38. PubMed ID: 17419952
[TBL] [Abstract][Full Text] [Related]
7. The p53 gene and its role in human brain tumors.
Bögler O; Huang HJ; Kleihues P; Cavenee WK
Glia; 1995 Nov; 15(3):308-27. PubMed ID: 8586466
[TBL] [Abstract][Full Text] [Related]
8. Functional inactivation of p53 by human T-cell leukemia virus type 1 Tax protein: mechanisms and clinical implications.
Tabakin-Fix Y; Azran I; Schavinky-Khrapunsky Y; Levy O; Aboud M
Carcinogenesis; 2006 Apr; 27(4):673-81. PubMed ID: 16308315
[TBL] [Abstract][Full Text] [Related]
9. p53 and its downstream proteins as molecular targets of cancer.
Sun Y
Mol Carcinog; 2006 Jun; 45(6):409-15. PubMed ID: 16652354
[TBL] [Abstract][Full Text] [Related]
10. p53 from basic research to clinical applications.
Tominaga O; Hamelin R; Remvikos Y; Salmon RJ; Thomas G
Crit Rev Oncog; 1992; 3(3):257-82. PubMed ID: 1616957
[TBL] [Abstract][Full Text] [Related]
11. New treatment strategies for malignant gliomas.
Sathornsumetee S; Rich JN
Expert Rev Anticancer Ther; 2006 Jul; 6(7):1087-104. PubMed ID: 16831080
[TBL] [Abstract][Full Text] [Related]
12. Comparative assessment of the functional p53 status in glioma cells.
Kim EL; Yoshizato K; Kluwe L; Meissner H; Warnecke G; Zapf S; Westphal M; Deppert W; Giese A
Anticancer Res; 2005; 25(1A):213-24. PubMed ID: 15816541
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic mutation of the p53 gene derived from head and neck cancer prevents cells from undergoing apoptosis after DNA damage.
Kawamata H; Omotehara F; Nakashiro K; Uchida D; Shinagawa Y; Tachibana M; Imai Y; Fujimori T
Int J Oncol; 2007 May; 30(5):1089-97. PubMed ID: 17390010
[TBL] [Abstract][Full Text] [Related]
14. Role of Stat3 in regulating p53 expression and function.
Niu G; Wright KL; Ma Y; Wright GM; Huang M; Irby R; Briggs J; Karras J; Cress WD; Pardoll D; Jove R; Chen J; Yu H
Mol Cell Biol; 2005 Sep; 25(17):7432-40. PubMed ID: 16107692
[TBL] [Abstract][Full Text] [Related]
15. Autocrine platelet-derived growth factor-dependent gene expression in glioblastoma cells is mediated largely by activation of the transcription factor sterol regulatory element binding protein and is associated with altered genotype and patient survival in human brain tumors.
Ma D; Nutt CL; Shanehsaz P; Peng X; Louis DN; Kaetzel DM
Cancer Res; 2005 Jul; 65(13):5523-34. PubMed ID: 15994924
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin and platinum drugs at the molecular level. (Review).
Boulikas T; Vougiouka M
Oncol Rep; 2003; 10(6):1663-82. PubMed ID: 14534679
[TBL] [Abstract][Full Text] [Related]
17. [Relevance of p53 protein and its mutations for novel strategies in cancer therapy].
Müller P; Nenutil R; Vojtĕsek B
Cas Lek Cesk; 2004; 143(5):313-7. PubMed ID: 15305766
[TBL] [Abstract][Full Text] [Related]
18. [Tumor suppressor gene p53--function and significance in gastroenterology].
Schoppmeyer K; Keim V; Mössner J
Z Gastroenterol; 1997 Jun; 35(6):491-509. PubMed ID: 9281241
[TBL] [Abstract][Full Text] [Related]
19. p53 mutation heterogeneity in cancer.
Soussi T; Lozano G
Biochem Biophys Res Commun; 2005 Jun; 331(3):834-42. PubMed ID: 15865939
[TBL] [Abstract][Full Text] [Related]
20. Targeted repression of bone morphogenetic protein 7, a novel target of the p53 family, triggers proliferative defect in p53-deficient breast cancer cells.
Yan W; Chen X
Cancer Res; 2007 Oct; 67(19):9117-24. PubMed ID: 17909016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
